Recent Updates
Recently added Catalysts
IVVD Positive Sentiment Score: 75/100

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Key Takeaway: Invivyd, Inc. will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025. The company's management will engage in a fireside chat and conduct investor meetings during the event. Additionally, a live webcast of the discussion will be accessible on their website, providing an opportunity for broader investor engagement. Invivyd focuses on developing innovative antibody therapies for serious viral infections and recently received FDA emergency use authorization for one of its monoclonal antibodies.

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd will participate in a prominent investor conference.
  • Management will host sessions to engage with investors.
  • The company has received emergency use authorization from the FDA for a monoclonal antibody.

Full Press Release Details

WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025, at 11:00 a.m. ET in New York, NY.
In addition to the fireside chat, the management team will host investor meetings at the conference. Investors participating in the conference who are interested in meeting with Invivyd management should contact their H.C. Wainwright representative.
A live webcast of the fireside chat will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the presentation.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Frequently Asked Questions

When is Invivyd's fireside chat scheduled?

The fireside chat is on May 20, 2025, at 11:00 a.m. ET.

Where will the BioConnect Investor Conference take place?

The conference will be held in New York, NY.

How can investors meet Invivyd management?

Investors should contact their H.C. Wainwright representative.

Will the fireside chat be available for later viewing?

Yes, it will be archived for about 30 days on their website.

What is Invivyd focused on developing?

Invivyd focuses on creating protection against serious viral infections.

Last updated: May 13, 2025